Related Experiment Video
Updated: Aug 9, 2026

G2-seq: A High Throughput Sequencing-based Technique for Identifying Late Replicating Regions of the Genome
Published on: March 22, 2018
SGN-30 (Seattle genetics)
Roland Schnell1, Peter Borchmann
1Department of Internal Medicine I, University of Cologne, Joseph-Stelzmann-Strasse 9, D-50924 Cologne, Germany. roland.schnell@uni-koeln.de
Abstract:
Seattle Genetics is developing SGN-30, an intravenously administered recombinant anti-CD30 monoclonal antibody for the potential treatment of Hodgkin's disease, certain non-Hodgkin's lymphomas, specific leukemia, and immunological diseases such as multiple sclerosis and systemic lupus erythematosus. Phase II trials in patients with Hodgkin's disease, anaplastic large cell lymphoma, and cutaneous lymphoma have been conducted in the U.S. and Europe.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Incomplete Dominance
Pleiotropy

